EC4 Real-World Healthcare Costs in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the United States
Jun 1, 2021, 00:00
10.1016/j.jval.2021.04.029
https://www.valueinhealthjournal.com/article/S1098-3015(21)00246-1/fulltext
Title :
EC4 Real-World Healthcare Costs in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the United States
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)00246-1&doi=10.1016/j.jval.2021.04.029
First page :
Section Title :
Open access? :
No
Section Order :
10828